View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 23, 2022

Code Bio and Takeda collaborate to develop gene therapies for rare diseases

The deal value of the partnership totals to up to $2bn if milestones for all four programmes are met.

Code Biotherapeutics and Takeda have entered a partnership and option agreement for designing and developing gene therapies to treat rare diseases.

The targeted 3DNA non-viral genetic medicine delivery platform of Code Bio will be used to develop these treatments.

According to the collaboration, the companies will use the 3DNA platform to design and develop targeted gene therapy for a liver-directed rare disease programme.

In addition, Takeda and Code Bio will carry out further studies for central nervous system-directed programmes. 

Under the deal, Takeda holds the right to exercise options to obtain an exclusive licence for four programmes. 

Code Bio is entitled to receive upfront, near-term milestones and research funding payments in the range of double-digit million dollars from Takeda. 

Takeda will make development and commercial milestone payments apart from tiered royalty payments in the future.

This takes the potential deal value of the collaboration to a total of up to $2bn on meeting milestones for all four programmes.

Initially, the companies will work together on research activities till the selection of the candidates. 

Following the subsequent option exercise, Takeda will oversee the development and marketing of the programmes.

​Takeda Pharmaceutical Rare Diseases Drug Discovery Unit head Madhu Natarajan said: “We aim to provide functional cures to patients with rare genetic and hematologic diseases through next-generation gene therapy programmes. 

“Code Bio’s 3DNA platform will allow us to build upon the foundation we have established through our internal capabilities and external partnerships and will hopefully enable us to develop re-dosable and durable gene therapies that will be superior to current approaches.”

The 3DNA platform can address crucial drawbacks of various other genetic medicine delivery methods permitting genetic therapies to reach their maximum potential. 

In October last year, Takeda and Immusoft signed a research and licensing agreement to develop cell therapies for rare neurometabolic disorders.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU